Executive Officer Notice: End of Funding of Braftovi ® (encorafenib) and Vectibix ® (panitumumab) in the treatment of treatment-naïve patients with BRAF V600E-mutated metastatic colorectal cancer

Ontario Public Drug Programs notice (PDF) for pharmacies and dispensers.

ScopeUp collects Ontario and national pharmacy practice updates and links every item to its source. Verify details against the source document before changing workflows.